Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy
Cervical cancer (CC) is one of the most common cancers in women and virtually all cases of CC are a result of a persistent infection of human papillomavirus (HPV). For disease detected in early stages there is curing treatment but when diagnosed late with recurring disease and metastasis there are l...
Uloženo v:
| Vydáno v: | Oncotarget Ročník 9; číslo 27; s. 18786 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
10.04.2018
|
| Témata: | |
| ISSN: | 1949-2553, 1949-2553 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cervical cancer (CC) is one of the most common cancers in women and virtually all cases of CC are a result of a persistent infection of human papillomavirus (HPV). For disease detected in early stages there is curing treatment but when diagnosed late with recurring disease and metastasis there are limited possibilities. Here we evaluate HPV impact on treatment resistance and metastatic disease progression. Prevalence and distribution of HPV genotypes and HPV16 variants in a Swedish CC patient cohort (n=209) was evaluated, as well as HPV influence on patient prognosis. Tumor samples suitable for analysis (n=204) were genotyped using two different real-time PCR methods. HPV16 variant analysis was made using pyrosequencing. Results showed that HPV prevalence in the total series was 93%. Of the HPV-positive samples, 13% contained multiple infections, typically with two high-risk HPV together. Primary cure rate for the complete series was 95%. Recurrence rate of the complete series was 28% and distant recurrences were most frequent (20%). Patients with tumors containing multiple HPV-strains and particularly HPV genotypes belonging to the alpha 7 and 9 species together had a significantly higher rate of distant tumor recurrences and worse cancer-specific survival rate. |
|---|---|
| AbstractList | Cervical cancer (CC) is one of the most common cancers in women and virtually all cases of CC are a result of a persistent infection of human papillomavirus (HPV). For disease detected in early stages there is curing treatment but when diagnosed late with recurring disease and metastasis there are limited possibilities. Here we evaluate HPV impact on treatment resistance and metastatic disease progression. Prevalence and distribution of HPV genotypes and HPV16 variants in a Swedish CC patient cohort (n=209) was evaluated, as well as HPV influence on patient prognosis. Tumor samples suitable for analysis (n=204) were genotyped using two different real-time PCR methods. HPV16 variant analysis was made using pyrosequencing. Results showed that HPV prevalence in the total series was 93%. Of the HPV-positive samples, 13% contained multiple infections, typically with two high-risk HPV together. Primary cure rate for the complete series was 95%. Recurrence rate of the complete series was 28% and distant recurrences were most frequent (20%). Patients with tumors containing multiple HPV-strains and particularly HPV genotypes belonging to the alpha 7 and 9 species together had a significantly higher rate of distant tumor recurrences and worse cancer-specific survival rate.Cervical cancer (CC) is one of the most common cancers in women and virtually all cases of CC are a result of a persistent infection of human papillomavirus (HPV). For disease detected in early stages there is curing treatment but when diagnosed late with recurring disease and metastasis there are limited possibilities. Here we evaluate HPV impact on treatment resistance and metastatic disease progression. Prevalence and distribution of HPV genotypes and HPV16 variants in a Swedish CC patient cohort (n=209) was evaluated, as well as HPV influence on patient prognosis. Tumor samples suitable for analysis (n=204) were genotyped using two different real-time PCR methods. HPV16 variant analysis was made using pyrosequencing. Results showed that HPV prevalence in the total series was 93%. Of the HPV-positive samples, 13% contained multiple infections, typically with two high-risk HPV together. Primary cure rate for the complete series was 95%. Recurrence rate of the complete series was 28% and distant recurrences were most frequent (20%). Patients with tumors containing multiple HPV-strains and particularly HPV genotypes belonging to the alpha 7 and 9 species together had a significantly higher rate of distant tumor recurrences and worse cancer-specific survival rate. Cervical cancer (CC) is one of the most common cancers in women and virtually all cases of CC are a result of a persistent infection of human papillomavirus (HPV). For disease detected in early stages there is curing treatment but when diagnosed late with recurring disease and metastasis there are limited possibilities. Here we evaluate HPV impact on treatment resistance and metastatic disease progression. Prevalence and distribution of HPV genotypes and HPV16 variants in a Swedish CC patient cohort (n=209) was evaluated, as well as HPV influence on patient prognosis. Tumor samples suitable for analysis (n=204) were genotyped using two different real-time PCR methods. HPV16 variant analysis was made using pyrosequencing. Results showed that HPV prevalence in the total series was 93%. Of the HPV-positive samples, 13% contained multiple infections, typically with two high-risk HPV together. Primary cure rate for the complete series was 95%. Recurrence rate of the complete series was 28% and distant recurrences were most frequent (20%). Patients with tumors containing multiple HPV-strains and particularly HPV genotypes belonging to the alpha 7 and 9 species together had a significantly higher rate of distant tumor recurrences and worse cancer-specific survival rate. |
| Author | Lillsunde-Larsson, Gabriella Sorbe, Bengt Karlsson, Mats G Mordhorst, Louise Bohr Kaliff, Malin Helenius, Gisela |
| Author_xml | – sequence: 1 givenname: Malin surname: Kaliff fullname: Kaliff, Malin organization: Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro SE 701 82, Sweden – sequence: 2 givenname: Bengt surname: Sorbe fullname: Sorbe, Bengt organization: Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro SE 701 82, Sweden – sequence: 3 givenname: Louise Bohr surname: Mordhorst fullname: Mordhorst, Louise Bohr organization: Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro SE 701 82, Sweden – sequence: 4 givenname: Gisela surname: Helenius fullname: Helenius, Gisela organization: Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro SE 701 82, Sweden – sequence: 5 givenname: Mats G surname: Karlsson fullname: Karlsson, Mats G organization: Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro SE 701 82, Sweden – sequence: 6 givenname: Gabriella surname: Lillsunde-Larsson fullname: Lillsunde-Larsson, Gabriella organization: Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro SE 701 82, Sweden |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29721161$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtOwzAQRS0Eojz6AWyQl2xSbCexmyWqKCBVAonHtnLscWuU2MF2qPph_B-pANHZzCzOPaOZU3TovAOELiiZ0CnP2bV3yicZVpAmrOCcH6ATWhVVxsoyP9ybR2gc4zsZqizElFXHaMQqwSjl9AR9za3T1q0i9ga3fZNs1wC-f3rDK3A-bTuI2DqsIHxaJRusZFDW-VZiGQDLGL2yMoHGG5vWuPM-DIgb8Cx2oKyxCsd-yH4O2cEj8fMGtI1rrPzah7TbuufeBXEXbCuDbbY4Bfh3B6mtT2sIstueoyMjmwjj336GXue3L7P7bPF49zC7WWQqLynPjDYqr3lJczFVpKolITWloqrLXGsjqOSiBC2mFIyipiRCFIbWrIKCU0YNYWfo6sfbBf_RQ0zL1kYFTSMd-D4uGckLVpGcFQN6-Yv2dQt6-XPFdvn3avYNo9CJZg |
| CitedBy_id | crossref_primary_10_1136_bmjopen_2018_028171 crossref_primary_10_3390_ijms22052294 crossref_primary_10_1007_s40944_020_00456_x crossref_primary_10_1371_journal_pone_0215222 crossref_primary_10_4103_jcrt_JCRT_177_19 crossref_primary_10_1371_journal_pone_0257324 crossref_primary_10_1186_s12985_024_02496_7 crossref_primary_10_1186_s13027_020_00332_5 crossref_primary_10_1007_s11547_020_01187_x crossref_primary_10_1097_PGP_0000000000000612 crossref_primary_10_1016_j_jviromet_2021_114193 crossref_primary_10_1016_j_pdpdt_2021_102454 crossref_primary_10_1155_2021_5555452 crossref_primary_10_1186_s40644_019_0226_4 crossref_primary_10_1016_j_ypmed_2021_106617 crossref_primary_10_3389_fimmu_2020_561843 crossref_primary_10_3390_microorganisms11010212 crossref_primary_10_3390_pathogens12030424 crossref_primary_10_1371_journal_pone_0218762 crossref_primary_10_1007_s40291_025_00809_2 crossref_primary_10_5858_arpa_2019_0199_OA crossref_primary_10_1002_cncy_22536 crossref_primary_10_1016_j_critrevonc_2020_103178 crossref_primary_10_3390_cancers15020347 crossref_primary_10_3390_v13020280 crossref_primary_10_3389_fonc_2023_1264114 crossref_primary_10_1177_10732748231176642 crossref_primary_10_3389_fonc_2021_752974 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.18632/oncotarget.24666 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1949-2553 |
| ExternalDocumentID | 29721161 |
| Genre | Journal Article |
| GroupedDBID | --- 53G ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK FRJ GX1 HYE KQ8 M48 NPM OK1 PGMZT RPM 7X8 |
| ID | FETCH-LOGICAL-c3516-fdfc3b651378c09ba00b1179b53ddf71a675ed781efc1f50774f1b29e46121f02 |
| IEDL.DBID | 7X8 |
| ISSN | 1949-2553 |
| IngestDate | Thu Oct 02 07:02:42 EDT 2025 Thu Apr 03 07:01:45 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 27 |
| Keywords | recurrences cervical cancer survival HPV |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3516-fdfc3b651378c09ba00b1179b53ddf71a675ed781efc1f50774f1b29e46121f02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=24666&path%5B%5D=77378 |
| PMID | 29721161 |
| PQID | 2034290324 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2034290324 pubmed_primary_29721161 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-04-10 |
| PublicationDateYYYYMMDD | 2018-04-10 |
| PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Oncotarget |
| PublicationTitleAlternate | Oncotarget |
| PublicationYear | 2018 |
| References | 8827013 - J Natl Cancer Inst. 1996 Oct 2;88(19):1361-8 12842378 - Lancet. 2003 Jun 28;361(9376):2217-25 17405118 - Int J Cancer. 2007 Aug 1;121(3):621-32 23749640 - Cancer Res. 2013 Aug 1;73(15):4791-800 16835323 - Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1274-80 25766614 - Jpn J Infect Dis. 2015;68(3):169-75 25325935 - Curr Oncol Rep. 2014 Dec;16(12):416 20952254 - Lancet Oncol. 2010 Nov;11(11):1048-56 25791291 - J Mol Diagn. 2015 May;17(3):293-301 11955748 - Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1345-51 26212178 - Am J Obstet Gynecol. 2016 Jan;214(1):22-30 21607093 - J Gynecol Oncol. 2011 Mar 31;22(1):32-8 16136457 - J Infect Dis. 2005 Oct 1;192(7):1158-65 20231068 - Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1111-20 8945623 - Int J Cancer. 1996 Nov 15;68(4):506-13 24740764 - Int J Cancer. 2014 Dec 1;135(11):2721-6 26735580 - Oncotarget. 2016 Feb 2;7(5):5852-64 11740725 - J Infect Dis. 2001 Dec 15;184(12):1508-17 23928291 - Virology. 2013 Oct;445(1-2):224-31 19082497 - Int J Oncol. 2009 Jan;34(1):263-71 22266551 - Gynecol Oncol. 2012 May;125(2):287-91 25708801 - Curr Oncol Rep. 2015 Apr;17(4):17 23189750 - IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441 23402906 - Gynecol Oncol. 2013 May;129(2):406-11 23447632 - J Clin Microbiol. 2013 May;51(5):1458-64 25043476 - Int J Cancer. 2015 Mar 1;136(5):1171-80 25889023 - Virol J. 2015 Feb 22;12:29 25855986 - PLoS One. 2015 Apr 09;10(4):e0122557 10926787 - Gynecol Oncol. 2000 Aug;78(2):97-105 18847553 - Vaccine. 2008 Aug 19;26 Suppl 10:K1-16 12397642 - Int J Cancer. 2002 Nov 20;102(3):237-43 16784783 - J Virol Methods. 2006 Sep;136(1-2):166-70 23013732 - Int J Gynecol Cancer. 2012 Oct;22(8):1413-9 16614130 - Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):820-2 28988982 - Virus Res. 2018 Jan 2;243:1-9 22132173 - PLoS One. 2011;6(11):e27937 |
| References_xml | – reference: 8827013 - J Natl Cancer Inst. 1996 Oct 2;88(19):1361-8 – reference: 12842378 - Lancet. 2003 Jun 28;361(9376):2217-25 – reference: 23447632 - J Clin Microbiol. 2013 May;51(5):1458-64 – reference: 19082497 - Int J Oncol. 2009 Jan;34(1):263-71 – reference: 20952254 - Lancet Oncol. 2010 Nov;11(11):1048-56 – reference: 21607093 - J Gynecol Oncol. 2011 Mar 31;22(1):32-8 – reference: 23013732 - Int J Gynecol Cancer. 2012 Oct;22(8):1413-9 – reference: 10926787 - Gynecol Oncol. 2000 Aug;78(2):97-105 – reference: 23402906 - Gynecol Oncol. 2013 May;129(2):406-11 – reference: 16784783 - J Virol Methods. 2006 Sep;136(1-2):166-70 – reference: 22132173 - PLoS One. 2011;6(11):e27937 – reference: 25766614 - Jpn J Infect Dis. 2015;68(3):169-75 – reference: 16835323 - Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1274-80 – reference: 25708801 - Curr Oncol Rep. 2015 Apr;17(4):17 – reference: 12397642 - Int J Cancer. 2002 Nov 20;102(3):237-43 – reference: 17405118 - Int J Cancer. 2007 Aug 1;121(3):621-32 – reference: 16614130 - Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):820-2 – reference: 25889023 - Virol J. 2015 Feb 22;12:29 – reference: 25325935 - Curr Oncol Rep. 2014 Dec;16(12):416 – reference: 23928291 - Virology. 2013 Oct;445(1-2):224-31 – reference: 22266551 - Gynecol Oncol. 2012 May;125(2):287-91 – reference: 26735580 - Oncotarget. 2016 Feb 2;7(5):5852-64 – reference: 28988982 - Virus Res. 2018 Jan 2;243:1-9 – reference: 8945623 - Int J Cancer. 1996 Nov 15;68(4):506-13 – reference: 24740764 - Int J Cancer. 2014 Dec 1;135(11):2721-6 – reference: 18847553 - Vaccine. 2008 Aug 19;26 Suppl 10:K1-16 – reference: 25855986 - PLoS One. 2015 Apr 09;10(4):e0122557 – reference: 20231068 - Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1111-20 – reference: 26212178 - Am J Obstet Gynecol. 2016 Jan;214(1):22-30 – reference: 25043476 - Int J Cancer. 2015 Mar 1;136(5):1171-80 – reference: 25791291 - J Mol Diagn. 2015 May;17(3):293-301 – reference: 11740725 - J Infect Dis. 2001 Dec 15;184(12):1508-17 – reference: 11955748 - Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1345-51 – reference: 16136457 - J Infect Dis. 2005 Oct 1;192(7):1158-65 – reference: 23189750 - IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441 – reference: 23749640 - Cancer Res. 2013 Aug 1;73(15):4791-800 |
| SSID | ssj0000547829 |
| Score | 2.35048 |
| Snippet | Cervical cancer (CC) is one of the most common cancers in women and virtually all cases of CC are a result of a persistent infection of human papillomavirus... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 18786 |
| Title | Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29721161 https://www.proquest.com/docview/2034290324 |
| Volume | 9 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaAcuBCi4DSlqKpxNXUjpM4OVWoYtULq5WgaG8rxw8RqU2WpC3aH9b_1xmvt3DooVIvOWUmiWYynuc3jH2WxmtnCsuL2mU8d1nOjSoFd0UTXG4aPIRcXDahp9NqPq9nKeE2prbKjU2Mhtr1lnLkGKQrNJ0Cz_-T5R9OW6OouppWaDxnWwpdGdJqPa_ucyyCwKriojIM1WuO3rNKhc2qVNlxT_AHsd_6S5aXCSfxQSczHjaT7ae-5g57ndxM-LrWizfsme_esttJG2dYRugDbDoJ4Wz2CwiplZKxI7Qd2Gg-kNrSnqGuvzRgBg8mCdI7oOQtLPt-wFtQaQZO85rUcwTjNdKi8hIfAz_-0tTvb6AtvMMVPfU_3kQIywh20V6sIHa8b3gPxrVpNGz1jp1Pvv08PeNpbQO3qpAlDy5Y1ZSFVLqyom6MEA0BzzWFci5oaTBG8U5X0gcrA_qjOg-yyWqfE5pZENl79qLrO_-BQWZMIbUIVe4whJelsRjB-uAsTfBraffY0UYKC_wtqNZhOt9fj4t_cthju2tRLtaftFpkhFiEnu7-I6gP2Ct0kSqqH0nxkW0FNAr-kL20N1ftOHyK-obX6ez7HXB35Wc |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Findings+of+multiple+HPV+genotypes+in+cervical+carcinoma+are+associated+with+poor+cancer-specific+survival+in+a+Swedish+cohort+of+cervical+cancer+primarily+treated+with+radiotherapy&rft.jtitle=Oncotarget&rft.au=Kaliff%2C+Malin&rft.au=Sorbe%2C+Bengt&rft.au=Mordhorst%2C+Louise+Bohr&rft.au=Helenius%2C+Gisela&rft.date=2018-04-10&rft.issn=1949-2553&rft.eissn=1949-2553&rft.volume=9&rft.issue=27&rft.spage=18786&rft_id=info:doi/10.18632%2Foncotarget.24666&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon |